Exchange: NASDAQ Sector: Healthcare Industry: Medical Instruments & Supplies
Current Signal: SELL (auto-tracking)
6.76% $15.63
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 1 673.86 mill |
EPS: | -1.950 |
P/E: | -8.02 |
Earnings Date: | Jan 08, 2024 |
SharesOutstanding: | 107.09 mill |
Avg Daily Volume: | 1.383 mill |
RATING 2024-03-28 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Strong Buy | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -8.02 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.24x |
Company: PE -8.02 | industry: PE 33.06 |
DISCOUNTED CASH FLOW VALUE |
---|
$2.58 (-83.50%) $-13.05 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 14.65 - 16.61 ( +/- 6.27%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-01 | Groenhuysen Wilhelmus Cm | Sell | 2 107 | Ordinary Shares |
2024-03-04 | Groenhuysen Wilhelmus Cm | Sell | 1 217 | Ordinary Shares |
2024-03-01 | Leonard Frank X | Sell | 1 679 | Ordinary Shares |
2024-03-04 | Leonard Frank X | Sell | 840 | Ordinary Shares |
2024-02-27 | Cordova Ashley | Buy | 102 249 | Ordinary Shares |
INSIDER POWER |
---|
77.53 |
Last 92 transactions |
Buy: 1 705 026 | Sell: 238 995 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $15.63 (6.76% ) |
Volume | 2.40 mill |
Avg. Vol. | 1.383 mill |
% of Avg. Vol | 173.81 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:36 | sell | $14.68 | N/A | Active |
---|
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.